Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B1 | P15121 | 5/20 | 0.40 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.37 |
| ▸ | SRD5A1 | P18405 | 2/20 | 0.36 |
| ▸ | PARK7 | Q99497 | 3/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | CA7 | P43166 | 1/20 | 0.34 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
| ▸ | PARP1 | P09874 | 1/20 | 0.34 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.34 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.34 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.33 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18863191 | 0.81 | HDAC4 (0.35) | AKR1B1HDAC4ACHESRD5A1PARK7 | |
| SCHEMBL30620824 | 0.77 | HRH3 (0.52) | HRH3 | |
| SCHEMBL17254689 | 0.77 | PARK7 (0.39) | AKR1B1ACHESRD5A1PARK7CA1 | |
| SCHEMBL20672175 | 0.76 | METAP1 (0.38) | AKR1B1ACHEHRH3CA1CA2 | |
| SCHEMBL22898412 | 0.74 | NR1H2 (0.40) | HRH3DDB1CRBN | |
| SCHEMBL20078907 | 0.74 | EGFR (0.40) | HRH3CA1CA2CA7CA9 | |
| SCHEMBL30564277 | 0.73 | HRH3 (0.52) | HRH3 | |
| SCHEMBL25453061 | 0.73 | KDM4E (0.37) | AKR1B1SRD5A1HRH3CA1CA2 | |
| SCHEMBL29813861 | 0.72 | MEN1 (0.39) | AKR1B1SRD5A1HRH3CA1CA2 | |
| SCHEMBL25457843 | 0.70 | HRH3 (0.36) | AKR1B1SRD5A1HRH3CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10336736-B2 | Modulators of chemokine receptors | CHEMOCENTRYX, INC. (US) | 2019-07-02 | — | — | US | disclosed |
| US-20180141934-A1 | MODULATORS OF CHEMOKINE RECEPTORS | CHEMOCENTRYX, INC. | 2018-05-24 | — | — | US | disclosed |
| US-20180141934-A1 | MODULATORS OF CHEMOKINE RECEPTORS | CHEMOCENTRYX, INC. | 2018-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10336736-B2 | Modulators of chemokine receptors | CCR5, CXCR3, CCR2 | AKR1B1 2186/4885HDAC4 2302/4885ACHE 4820/4885 |
| US-20180141934-A1 | MODULATORS OF CHEMOKINE RECEPTORS | CCR5, CXCR3, CCR2 | AKR1B1 2186/4885HDAC4 2302/4885ACHE 4820/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.